RESUMEN
We reported a rare case of peritoneal dialysis-associated peritonitis caused by Weissella confusa. In this case, the symptoms of peritonitis were insidious and atypical, with only turbid peritoneal dialysis effluent and no fever or abdominal pain. The peritoneal dialysis effluent showed slightly elevated leukocytes (predominantly lymphocytes). Weissella confusa was confirmed through repeated peritoneal dialysis effluent cultures. Gastroscopy revealed erosive gastritis with a hookworm infection. The patient recovered after antibiotic and deworming treatments. Our report highlights the unusual and atypical symptoms, characterized by insidious onset, turbid peritoneal dialysis fluid, and an absence of typical signs such as fever or abdominal pain.
RESUMEN
BACKGROUND: There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with the prognosis in multiple types of cancers. Like in cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationships between the ALI and all-cause and cardiovascular disease (CVD) mortality in PD patients. METHODS: Patients who started PD at Shaoxing People's Hospital between 1 January 2013 and 31 December 2020 (n = 277) were recruited and followed up until 1 July 2023. They were divided into high-ALI group and low-ALI group according to the median of ALI. Kaplan-Meier curves and multivariate Cox regression analyses were used to assess the associations between the ALI and all-cause and CVD mortality. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to determine the predictive power of the ALI for all- cause and CVD mortality. RESULTS: During the median follow-up of 40.50 months (interquartile range, 26.42-59.77 months), a total of 55 patients died, 31 of whom died due to CVD. Kaplan-Meier curves revealed that patients in the low-ALI group had significantly lower cumulative and cardiovascular cumulative survival rates than did those in the high-ALI group (all P < 0.001). After we corrected for confounders, the risk of all-cause and CVD mortality was significantly greater in the low-ALI group than in the high-ALI group [hazard ratio (HR) 1.944, 95% confidence interval (CI) 1.068-3.540, P = 0.030, and HR 2.672, 95% CI 1.188-6.009, P = 0.017, respectively]. The predictive value of ALI (AUC = 0.708, 95% CI 0.630-0.786, P < 0.001) for all-cause mortality was superior to albumin (AUC = 0.644, 95% CI 0.556-0.726, P < 0.001), body mass index (AUC = 0.581, 95% CI 0.496-0.659, P = 0.069) and neutrophil-to-lymphocyte ratio (AUC = 0.675, 95% CI 0.596-0.754, P < 0.001). CONCLUSION: A lower ALI is an independent risk factor for all-cause and cardiovascular mortality in PD patients. The ALI may be an effective indicator for predicting outcomes in PD patients.
Asunto(s)
Inflamación , Neoplasias Pulmonares , Diálisis Peritoneal , Humanos , Masculino , Femenino , Persona de Mediana Edad , Neoplasias Pulmonares/mortalidad , Enfermedades Cardiovasculares/mortalidad , Anciano , Causas de Muerte , Adulto , Estimación de Kaplan-Meier , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/terapia , Curva ROC , PronósticoRESUMEN
INTRODUCTION: Sarcopenia is associated with significant cardiovascular risk, and death in patients undergoing peritoneal dialysis (PD). Three tools are used for diagnosing sarcopenia. The evaluation of muscle mass requires dual energy X-ray absorptiometry (DXA) or computed tomography (CT), which is labor-intensive and relatively expensive. This study aimed to use simple clinical information to develop a machine learning (ML)-based prediction model of PD sarcopenia. METHODS: According to the newly revised Asian Working Group for Sarcopenia (AWGS2019), patients were subjected to complete sarcopenia screening, including appendicular skeletal muscle mass, grip strength, and five-time chair stand time test. Simple clinical information such as general information, dialysis-related indices, irisin and other laboratory indices, and bioelectrical impedance analysis (BIA) data were collected. All data were randomly split into training (70%) and testing (30%) sets. Difference, correlation, univariate, and multivariate analyses were used to identify core features significantly associated with PD sarcopenia. RESULT: 12 core features (C), namely, grip strength, body mass index (BMI), total body water value, irisin, extracellular water/total body water, fat-free mass index, phase angle, albumin/globulin, blood phosphorus, total cholesterol, triglyceride, and prealbumin were excavated for model construction. Two ML models, the neural network (NN), and support vector machine (SVM) were selected with tenfold cross-validation to determine the optimal parameter. The C-SVM model showed a higher area under the curve (AUC) of 0.82 (95% confidence interval [CI]: 0.67-1.00), with a highest specificity of 0.96, sensitivity of 0.91, positive predictive value (PPV) of 0.96, and negative predictive value (NPV) of 0.91. CONCLUSION: The ML model effectively predicted PD sarcopenia and has clinical potential to be used as a convenient sarcopenia screening tool.
Asunto(s)
Diálisis Peritoneal , Sarcopenia , Humanos , Sarcopenia/diagnóstico , Sarcopenia/etiología , Sarcopenia/patología , Músculo Esquelético/patología , Fibronectinas , Diálisis Renal , Impedancia Eléctrica , Diálisis Peritoneal/efectos adversos , Absorciometría de Fotón/métodosRESUMEN
Podocytes play important roles in the progression of diabetic kidney disease (DKD) and these roles are closely associated with cytoskeletal actin dynamics. N-Methyl-d-aspartate receptors (NMDARs), which consist of two functional NR1 subunits and two regulatory NR2 subunits, are widely expressed in the brain but are also found in podocytes. Here, we found increased NR1 expression in two diabetic mouse models and in podocytes incubated in high glucose (HG). In diabetic mice, knockdown of NR1 using lentivirus carrying NR1-shRNA ameliorated the pathological features associated with DKD, and reversed the decreased expression of synaptopodin and Wilms' tumour-1. In podocytes incubated with HG, NR1 was secreted from the endoplasmic reticulum and this was blocked by bisindolylmaleimide I. NR1 knockdown decreased the cell shape remodelling, cell collapse, bovine serum albumin permeability, and migration induced by HG. After HG incubation, levels of cell division control protein 42 (Cdc42) and its active form increased, and a significantly higher Cdc42-GTP level, increased Cdc42 translocation onto the leading edges, and lower migration ability were found in podocytes with NR1 knockdown. Increases in the number and length of filopodia were found in podocytes with NR1 knockdown but these were abolished by Cdc42-GTP blockade with ML141. In conclusion, the activation of NMDARs plays an important role in DKD by reducing Cdc42-GTP activation. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Nefropatías Diabéticas/metabolismo , Riñón/metabolismo , Podocitos/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Proteína de Unión al GTP cdc42/metabolismo , Animales , Movimiento Celular/efectos de los fármacos , Movimiento Celular/fisiología , Forma de la Célula/efectos de los fármacos , Forma de la Célula/fisiología , Diabetes Mellitus Experimental/patología , Nefropatías Diabéticas/patología , Progresión de la Enfermedad , Glucosa/farmacología , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Masculino , Ratones , Ratones Transgénicos , Proteínas de Microfilamentos/genética , Proteínas de Microfilamentos/metabolismo , Podocitos/efectos de los fármacos , Podocitos/patología , Receptores de N-Metil-D-Aspartato/genéticaRESUMEN
AIM: Early intervention in patients with chronic kidney disease (CKD) significantly improves the prognosis. The present widely used markers of renal function, such as serum creatinine (sCr), fail to reflect early renal damage and predict the progression of disease. The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD. METHODS: We identified 92 patients with stage 2-4 CKD caused by primary chronic glomerulonephritis. The patients were followed for 2 years, the changes in NGAL levels in the progressive and non-progressive groups were compared. RESULTS: First, the serum NGAL levels of patients with stage 2-4 CKD were significantly increased compared with the control group. Second, based on Pearson correlation analysis, positive correlations existed between NGAL and cystatin C levels and between NGAL and sCr levels. Third, bounded by the progress of renal function, the area under the curve of serum NGAL was 0.872 (95% confidence interval, 0.786-0.933), which suggests a blood NGAL cut-off level of 246 ng/mL (sensitivity 85.19%, specificity 81.54%). Fourth, Kaplan-Meier survival curve analysis showed that the serum NGAL level was closely related to the end-point of renal function in patients with CKD. Fifth, Cox multivariate regression analysis showed that the estimated glomerular filtration rate and blood NGAL are associated with progression of CKD. CONCLUSION: Serum NGAL is an effective biomarker for detecting early-stage renal damage in CKD patients. Serum NGAL was significantly correlated with the severity of renal damage and the progression of renal function deterioration.
Asunto(s)
Cistatina C/sangre , Lipocalinas/sangre , Proteínas Proto-Oncogénicas/sangre , Insuficiencia Renal Crónica/sangre , Proteínas de Fase Aguda , Adulto , Anciano , Creatinina/sangre , Femenino , Tasa de Filtración Glomerular , Humanos , Lipocalina 2 , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Insuficiencia Renal Crónica/mortalidad , Insuficiencia Renal Crónica/fisiopatologíaRESUMEN
BACKGROUND: Cardiovascular disease (CVD) is an important cause of morbidity and mortality in peritoneal dialysis (PD) patients. Cardiovascular calcification (CVC) is highly prevalent in PD patients and could predict their cardiovascular mortality. Soluble urokinase plasminogen activator receptor (suPAR) is closely associated with coronary artery calcification in hemodialysis patients and is an important predictor of CVD. However, the role of suPAR in PD patients is poorly understood. We investigated the relationship between serum suPAR and CVC in PD patients. METHODS: Abdominal aortic calcification (AAC) was assessed by lateral lumbar radiography, coronary artery calcification (CAC) by multi-slice computed tomography, and cardiac valvular calcification (ValvC) by echocardiography. CVC was defined as confirmed presence of calcification in one site (AAC, CAC, or ValvC). Patients were divided into CVC group and non-CVC group. Demographic characteristics, biochemical variables, comorbidities, PD regimen, serum suPAR, and medication were compared between the two groups. Logistic regression was conducted to determine association between serum suPAR and presence of CVC. The receiver-operator curve (ROC) was plotted to calculate the area under the curve (AUC) for suPAR to identify CVC and ValvC. RESULTS: Of 226 PD patients, 111 (49.1%) had AAC, 155 (68.6%) had CAC, and 26 (11.5%) had ValvC. There were significant differences in age, BMI, diabetes, white blood cell, phosphorus, hs-CRP, suPAR, time on dialysis, total volume of dialysate, ultrafiltration, volume of urine, and Kt/V between CVC and non-CVC group. Serum suPAR was associated with CVC by multivariate logistic regression analysis in PD patients, especially in elderly patients. The levels of serum suPAR were closely related to the degree of AAC, CAC, and ValvC in PD patients. The incidence of CVC was higher in patients with higher levels of suPAR. The ROC curve showed that serum suPAR had a predictive value for CVC (AUC = 0.651), especially for ValvC (AUC = 0.828). CONCLUSION: Cardiovascular calcification is prevalent in PD patients. High levels of serum suPAR are associated with cardiovascular calcification in PD patients, especially in elderly patients.
Asunto(s)
Calcinosis , Enfermedades Cardiovasculares , Enfermedad de la Arteria Coronaria , Diálisis Peritoneal , Humanos , Biomarcadores , Enfermedad de la Arteria Coronaria/epidemiología , Diálisis Peritoneal/efectos adversos , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Factores de RiesgoRESUMEN
This study aims to investigate the impact of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) on vascular calcification in rats. The rationale behind studying ENPP1's role in vascular calcification lies in its potential to modulate calcification processes. Understanding this relationship can offer insights into novel therapeutic avenues for addressing vascular calcification-related disorders. In this experiment, vascular smooth muscle cell (VSMC) calcification was induced using ß-glycerophosphoric acid. Subsequently, recombinant AAV9-carrying ENPP1 was introduced into VSMCs to achieve both in vitro and in vivo overexpression of ENPP1. The findings indicate that ENPP1 overexpression significantly reduces calcium and phosphorus content in the aorta (P < 0.05). Alizarin red and von Kossa staining reveal notable reductions in calcium salt deposits in VSMCs and aorta, respectively. Notably, the expression levels of BMP-2, PINP, OC, and BALP were substantially decreased in VSMCs (P < 0.05), underscoring ENPP1's role in impeding osteoblast-like transdifferentiation of VSMCs. Additionally, ENPP1 overexpression led to a significant increase in pyrophosphate (PPi) levels compared to control rats (P < 0.05). In conclusion, this study suggests that ENPP1 contributes to alleviating vascular calcification by elevating PPi levels and inhibiting the phenotypic transformation of VSMCs. These findings shed light on the potential therapeutic role of ENPP1 in mitigating vascular calcification-related complications.
RESUMEN
BACKGROUND: Cardiovascular events (CVE) are the leading cause of death in peritoneal dialysis (PD) patients. The predictive value of cardiac valve calcification (CVC) for CVE in dialysis patients remains controversial. In particular, such studies are limited in PD patients. We aimed to examine the predictive role of CVC for CVE and cardiovascular mortality in PD patients. METHODS: A retrospective analysis was performed on patients who initiated PD in our hospital. According to the result of echocardiography, patients were divided into CVC group and non-CVC group. The differences in baseline demographic characteristics, biochemical variables, comorbidities, and clinical outcomes between the two groups were compared. Kaplan-Meier method was used to obtain survival curves. The Cox regression model was used to evaluate the influence of CVC for cardiovascular outcomes. The inverse probability of treatment weighting (IPTW) was used to eliminate influence of the confounders in the groups. RESULTS: 458 peritoneal dialysis patients were enrolled in this study. 77 patients were in CVC group and 381 patients in non-CVC group. The average follow-up time was (32 ± 21) months. At baseline, the absolute standardized difference (ASD) of age, BMI, history of CVE, diabetes, LVEF, LVMI, albumin, calcium, phosphorus, triglycerides, hsCRP, urine volume, Kt/V, statins and vitamin D intake rate were greater than 0.1 between the two groups. All of ASD dropped to less than 0.1 after IPTW, which meant that the balance had been reached between the two groups. Multivariable logistic analysis showed that advanced age, diabetes, and hyperphosphatemia were associated with CVC. The Kaplan-Meier survival curve showed the cumulative CVE-free survival rate and cardiovascular survival rate of CVC group were significantly lower than that of non-CVC group before and after IPTW (log-rank P < 0.05). After IPTW was used to eliminate the effect of confounders, multivariate Cox regression analysis still showed CVC was an independent risk factor for CVE (HR = 2.383, 95% CI 1.331~4.264, P = 0.003) and cardiovascular mortality (HR = 2.347, 95% CI 1.211~4.548, P = 0.012) in PD patients. CONCLUSION: The prevalence of CVC is high in peritoneal dialysis patients. CVC is an independent risk factor for CVE and cardiovascular mortality in peritoneal dialysis patients.
Asunto(s)
Enfermedades Cardiovasculares , Enfermedades de las Válvulas Cardíacas , Diálisis Peritoneal , Humanos , Estudios Retrospectivos , Enfermedades de las Válvulas Cardíacas/complicaciones , Enfermedades de las Válvulas Cardíacas/epidemiología , Diálisis Peritoneal/efectos adversos , Diálisis Peritoneal/métodos , Probabilidad , Válvulas Cardíacas , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiologíaRESUMEN
Background: Sarcopenia is associated with significant morbidity and mortality in patients undergoing peritoneal dialysis (PD). Three different tools must be applied to measure the three indices for diagnosing sarcopenia. Considering the cumbersome diagnostic steps and multi-layered mechanisms underlying sarcopenia, we combined new biomarker with bioelectrical impedance analysis (BIA) data to predict PD sarcopenia. Methods: Patients underwent regular PD were asked to complete sarcopenia screening, including appendicular skeletal muscle mass, handgrip strength, and the 5-time chair stand time test according to the newly revised diagnosis consensus of Asian Working Group for Sarcopenia (AWGS2019). Serum was collected for centralized detection of the irisin levels. BIA data, especially the phase angle (PhA), as well as patient's general clinical information, dialysis related indices, laboratory data and body composition data were recorded. Results: Among 105 enrolled PD patients (41.0% men, mean age 54.2 ± 8.89 years), the sarcopenia prevalence was 31.4% and the sarcopenic obesity was 8.6%. Binary regression analysis showed that serum irisin concentrations (OR = 0.98; 95% CI,0.97-0.99; p = 0.002), PhA (OR = 0.43; 95% CI, 0.21-0.90; p = 0.025) and body mass index (BMI) (OR = 0.64; 95% CI, 0.49-0.83; p = 0.001) were independently associated with PD sarcopenia. The AUC of the combination use of serum irisin concentrations and PhA for predicting PD sarcopenia was 0.925 with a sensitivity of 100% and specificity of 84.0% in male and was 0.880 with a sensitivity of 92.0% and specificity of 81.5% in female. PD sarcopenia score=1533.48+-0.75*Handgrip strength+4.63*BMI+-18.07*Total body water +-11.87*Extra-cellular water / total body water +9.26*Fat free mass index+-83.41*PhA+22.42*Albumin/Globulin+-26.38*blood phosphorus+-17.04*Total cholesterol+-29.02*Triglyceride+-0.29*Prealbumin+-0.17*Irisin. Conclusions: Sarcopenia is relatively common among PD patients. The combination of serum irisin concentrations and PhA facilitated the rapid prediction of PD sarcopenia and could serve as an optimal screening tool for PD sarcopenia in clinical settings.
Introduction: La sarcopénie est associée à une morbidité et une mortalité importantes chez les patients sous dialyse péritonéale (DP). Trois outils différents doivent être appliqués pour mesurer les trois indices de diagnostic de la sarcopénie. Compte tenu des étapes de diagnostic fastidieuses et des mécanismes multicouches sous-jacents à la sarcopénie, nous avons combiné un nouveau biomarqueur avec des données d'analyse d'impédance bioélectrique (BIA) pour prédire la sarcopénie. Méthodes: Les patients ayant subi une DP régulière ont été invités à compléter le dépistage de la sarcopénie, y compris la qualité du muscle squelettique des membres, la force de préhension et le test de temps debout sur chaise à cinq reprises, conformément au consensus de diagnostic nouvellement révisé du Groupe de travail asiatique sur la sarcopénie (AWGS2019). Le sérum a été recueilli pour la détection centralisée des niveaux d'irisine. Les données BIA, en particulier l'angle de phase (PhA), ainsi que les informations cliniques générales du patient, les indices liés à la dialyse, les données de laboratoire et les données de composition corporelle ont été enregistrés. Résultats. Parmi les 105 patients sous DP inscrits (41,0 % d'hommes, âge moyen de 54,2 ± 8,89 ans), la prévalence de la sarcopénie était de 31,4 % et l'obésité sarcopénique de 8,6 %. L'analyse de régression binaire a montré que les concentrations sériques d'irisine (OR = 0,98 ; IC à 95 % : 0,97-0,99 ; p = 0,002), PhA (OR = 0,43 ; IC à 95 % : 0,21-0,90 ; p = 0,025) et l'indice de masse corporelle (IMC) (OR = 0,64 ; IC à 95 % : 0,49-0,83 ; p = 0,001) étaient indépendamment associées à la sarcopénie DP. L'ASC de l'utilisation combinée des concentrations sériques d'irisine et du PhA pour prédire la sarcopénie était de 0,925 avec une sensibilité de 100 % et une spécificité de 84,0 % chez les hommes et était de 0,880 avec une sensibilité de 92,0 % et une spécificité de 81,5 % chez les femmes. Le score de sarcopénie DP était = 1 533,48 + -0,75 * Force de préhension + 4,63 * IMC + -18,07 * Eau corporelle totale + -11,87 * Eau extracellulaire / eau corporelle totale + 9,26 * Indice de masse sans graisse + -83,41 * PhA + 22,42 * Albumine / Globuline + -26,38 * Phosphore sanguin + -17,04 * Cholestérol total + -29,02 * Triglycérides + -0,29 * Préalbumine + -0,17 * Irisine. Conclusion: La sarcopénie est relativement fréquente chez les patients sous DP. La combinaison des concentrations sériques d'irisine et de PhA a facilité la prédiction rapide de la sarcopénie DP et pourrait servir d'outil de dépistage optimal de la sarcopénie DP en milieu clinique.
Asunto(s)
Diálisis Peritoneal , Sarcopenia , Humanos , Masculino , Femenino , Persona de Mediana Edad , Sarcopenia/diagnóstico , Sarcopenia/epidemiología , Sarcopenia/etiología , Fibronectinas , Fuerza de la Mano , Diálisis Peritoneal/efectos adversos , Diálisis Renal , Impedancia EléctricaRESUMEN
OBJECTIVE: To investigate the correlation between serum ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) level and severity of abdominal vascular calcification in end-stage renal disease (ESRD) patients receiving dialysis. METHODS: A total of 124 patients were consecutively enrolled into the study in our local institution. Based on the Kidney Disease Improving Global Outcomes (KDIGO) guidelines and recommendations, abdomen lateral X-ray was used to determine abdominal aortic calcification score (AACS) for each patient at enrollment. Patients were divided into three groups based on AACS: no or mild calcification group, moderate calcification group, and severe calcification group. The relationships between ENPP1 levels and AACS were assessed by Spearman analysis and the value of ENPP1 in predicting severity of abdominal aortic calcification was evaluated by receiver operating characteristic (ROC). RESULTS: The level of ENPP1 in dialysis patients was (7.68 ± 1.67) ng/ml. There was no significant difference in serum ENPP1 level between peritoneal dialysis patients and hemodialysis patients (p > 0.05). The AACS of dialysis patients was negatively correlated with ENPP1 value (r = -0.70). Compared to no/mild calcification patients, the levels of serum ENPP1 in patients with moderate/severe calcification were decreased significantly (p < 0.01). The severity of vascular calcification was correlated with serum ENPP1 value, the severer the vascular calcification, the lower the serum ENPP1 level, and the difference was statistically significant (all p < 0.05). The area under ROC curve of ENPP1 was 0.90, the corresponding sensitivity was 0.86, and the specificity was 0.87. CONCLUSION: Levels of serum ENPP1 in non-diabetic ESRD patients are negatively related to the severity of abdominal aortic vascular calcification.